RxDoctor Payments Data

Jennifer Fichera Macaluso, DO

Internal Medicine · Pembroke Pines, FLNPI 1114016052

Payments from drug & device makers

$1,350in general payments, 2019–2025

Across 78 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$267
  • AstraZeneca$241
  • Amgen$151
  • Johnson & Johnson$96
  • Pfizer$93
  • Lilly USA, LLC$90
  • plus $413 from 13 others

What the payments were for

  • Food & beverage$1,350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,350 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$49,260
Medicare patients
157
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$89,443
OzempicSemaglutide83$82,621
FarxigaDapagliflozin Propanediol80$80,713
MounjaroTirzepatide59$73,510
RybelsusSemaglutide42$50,226
JardianceEmpagliflozin25$27,255
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$26,416
ProliaDenosumab11$19,561
JanuviaSitagliptin Phosphate14$18,157
Breo ElliptaFluticasone/Vilanterol22$13,373
SynthroidLevothyroxine Sodium60$6,274
MyrbetriqMirabegron12$5,161
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,119
SymbicortBudesonide/Formoterol Fumarate15$4,051
Rosuvastatin Calcium336$3,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$267$132,847125 claims
PfizerEliquis$93$89,44383 claims
AstraZenecaFarxiga, Symbicort$241$84,76495 claims
Lilly USA, LLCMounjaro$90$73,51059 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$69$44,90849 claims
AmgenProlia$151$19,56111 claims
MerckJanuvia$35$18,15714 claims
AbbVieSynthroid$42$6,27460 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$20$1,956187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →